Search

Your search keyword '"Huntington, Scott F."' showing total 357 results
Start Over Author "Huntington, Scott F." Search Limiters Full Text Search Limiters Peer Reviewed
357 results on '"Huntington, Scott F."'

1. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Author

Bowers, Jackson T., Anna, Jacob, Bair, Steven M., Annunzio, Kaitlin, Epperla, Narendranath, Pullukkara, Jerrin Joy, Gaballa, Sameh, Spinner, Michael A., Li, Shuning, Messmer, Marcus R., Nguyen, Joseph, Ayers, Emily C., Wagner, Charlotte B., Hu, Boyu, Di, Mengyang, Huntington, Scott F., Furqan, Fateeha, Shah, Nirav N., Chen, Christina, Ballard, Hatcher J., Hughes, Mitchell E., Chong, Elise A., Nasta, Sunita D., Barta, Stefan K., Landsburg, Daniel J., and Svoboda, Jakub

Published
2023
Full Text
View/download PDF

4. Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis

Author

Bair, Steven M, Strelec, Lauren E, Feldman, Tatyana A, Ahmed, Gulrayz, Armand, Philippe, Shah, Nirav N, Singavi, Arun N, Reddy, Nishitha, Khan, Nadia, Andreadis, Charalambos, Vu, Khoan, Huntington, Scott F, Giri, Smith, Ujjani, Chaitra, Howlett, Christina, Faheem, Malik, Youngman, Matthew R, Nasta, Sunita D, Landsburg, Daniel J, Schuster, Stephen J, and Svoboda, Jakub

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Rare Diseases, Clinical Research, Cancer, Lymphoma, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions, Female, Follow-Up Studies, Hodgkin Disease, Humans, Male, Middle Aged, Nivolumab, Prognosis, Programmed Cell Death 1 Receptor, Retrospective Studies, Survival Rate, Young Adult, Hodgkin lymphoma, Immunotherapy, PD-1 inhibitor, Real-world, Checkpoint inhibitor, PD‐1 inhibitor, Real‐world, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BACKGROUND:Although classical Hodgkin lymphoma (cHL) is highly curable, 20%-30% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food and Drug Administration-approved for relapsed/refractory (R/R) cHL. There is limited data on the real-world experience with PD-1i in cHL and it is unknown whether fewer selected patients treated with PD-1i derive benefits similar to those observed in published trials. MATERIALS AND METHODS:We performed a multicenter, retrospective analysis of R/R cHL patients treated with PD-1i in the nontrial setting. The primary objective was to describe progression-free survival (PFS) and overall survival (OS) in this population. Secondary objectives were to characterize response rates, toxicities, discontinuation patterns, and post-PD-1i therapies. RESULTS:The study included 53 patients from nine U.S. centers. Overall response rate (ORR), complete response (CR), and partial response (PR) to PD-1i were 68%, 45%, and 23%, respectively. Twelve-month OS and PFS were 89% and 75%, respectively; median PFS was 29 months. Ninety-six percent of patients with CR continue to respond at a median follow-up of 20 months. Toxicities were similar to those previously described. Seventy percent of patients treated with systemic therapy after PD-1i demonstrated objective responses. CONCLUSION:To our knowledge, this analysis is the first describing real-world experience with PD-1i in cHL patients in the U.S. Here, we demonstrate similar response rates compared to prior studies. The toxicity profile of PD-1i was similar to that seen in previous studies; we further describe toxicity patterns in those with prior autoimmune disease or allogeneic transplant. Post-PD-1i systemic therapies appear active. These results support the effectiveness and tolerability of PD-1i therapy in R/R cHL in a real-world setting. IMPLICATIONS FOR PRACTICE:Two PD-1 inhibitors have recently been approved for patients with relapsed/refractory classical Hodgkin lymphoma based on results from nonrandomized clinical trials. However, to date, there have been no studies evaluating the effectiveness and toxicity profile of these drugs in the real-world setting in the U.S. The present study demonstrates that patients treated in a real-world context experience similar rates of overall effectiveness compared with published clinical trials. Patients who discontinue PD-1 inhibitors may experience clinical responses to subsequent treatment with systemic chemotherapy or targeted therapy. This study provides clinicians with further insight into the effectiveness and tolerability of PD-1 inhibitors and suggests that when patients progress while on these drugs, conventional systemic chemotherapy may be an effective treatment option.

Published
2019

6. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Author

Orellana-Noia, Victor Manuel, Reed, Daniel R., McCook, Ashley Alesia, Sen, Jeremy Michael, Barlow, Christian M., Malecek, Mary-Kate, Watkins, Marcus, Kahl, Brad S., Spinner, Michael A., Advani, Ranjana, Voorhees, Timothy J., Snow, Anson, Grover, Natalie Sophia, Ayers, Amy, Romancik, Jason, Liu, Yuxin, Huntington, Scott F., Chavez, Julio C., Saeed, Hayder, Lazaryan, Aleksandr, Raghunathan, Vikram, Spurgeon, Stephen E., Ollila, Thomas A., Del Prete, Christopher, Olszewski, Adam, Ayers, Emily C., Landsburg, Daniel J., Echalier, Benjamin, Lee, Jun, Kamdar, Manali, Caimi, Paolo F., Fu, Timothy, Liu, Jieqi, David, Kevin A., Alharthy, Hanan, Law, Jennie, Karmali, Reem, Shah, Harsh, Stephens, Deborah M., Major, Ajay, Rojek, Alexandra E., Smith, Sonali M., Yellala, Amulya, Kallam, Avyakta, Nakhoda, Shazi, Khan, Nadia, Sohail, Mohammad Ahsan, Hill, Brian T., Barrett-Campbell, Odeth, Lansigan, Frederick, Switchenko, Jeffrey, Cohen, Jonathon, and Portell, Craig A.

Published
2022
Full Text
View/download PDF

11. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia

Author

Podoltsev, Nikolai A., primary, Wang, Rong, additional, Shallis, Rory M., additional, Stempel, Jessica M., additional, Di, Mengyang, additional, Neparidze, Natalia, additional, Zeidan, Amer M., additional, Huntington, Scott F., additional, Giri, Smith, additional, Hull, Sarah C., additional, Gore, Steven D., additional, and Ma, Xiaomei, additional

Published
2023
Full Text
View/download PDF

13. DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study

Author

Huntington, Scott F., primary, Schuster, Stephen J., additional, Ding, Wei, additional, Koehler, Amber B., additional, Brander, Danielle M., additional, Rosenthal, Allison C., additional, Leis, Jose F., additional, Tun, Han W., additional, Moustafa, Muhamad Alhaj, additional, Iqbal, Madiha, additional, He, Wei, additional, Kearney, Albert S., additional, McKinlay, Timothy P., additional, Gui, Min, additional, and Mato, Anthony R., additional

Published
2023
Full Text
View/download PDF

16. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

Author

Di, Mengyang, primary, Long, Jessica B, additional, Kothari, Shalin K., additional, Sethi, Tarsheen, additional, Zeidan, Amer M., additional, Podoltsev, Nikolai A., additional, Shallis, Rory Michael, additional, Wang, Rong, additional, Stempel, Jessica M., additional, Ma, Xiaomei, additional, and Huntington, Scott F., additional

Published
2022
Full Text
View/download PDF

21. Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Author

De Nigris, Enrico, primary, Huntington, Scott F., additional, Puckett, Justin, additional, Kamal-Bahl, Sachin, additional, Farooqui, Mohammed Z.H., additional, Ryland, Katherine Elizabeth, additional, Sarpong, Eric, additional, Yang, Xiaoqin, additional, and Doshi, Jalpa, additional

Published
2022
Full Text
View/download PDF

22. Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Author

Huntington, Scott F., primary, De Nigris, Enrico, additional, Puckett, Justin, additional, Kamal-Bahl, Sachin, additional, Farooqui, Mohammed Z.H., additional, Ryland, Katherine Elizabeth, additional, Sarpong, Eric, additional, Yang, Xiaoqin, additional, and Doshi, Jalpa, additional

Published
2022
Full Text
View/download PDF

24. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia

Author

Bewersdorf, Jan Philipp, primary, Patel, Kishan K, additional, Goshua, George, additional, Shallis, Rory Michael, additional, Podoltsev, Nikolai A., additional, Stahl, Maximilian F., additional, Stempel, Jessica M., additional, Stein, Eytan, additional, Huntington, Scott F., additional, and Zeidan, Amer M., additional

Published
2022
Full Text
View/download PDF

29. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Author

Roeker, Lindsey Elizabeth, Eyre, Toby Andrew, Thompson, Meghan C., Lamanna, Nicole, Coltoff, Alexander, Davids, Matthew S., Baker, Peter, Leslie, Lori A., Rogers, Kerry A., Allan, John N., Cordoba, Raul, Lopez-Garcia, Alberto, Antic, Darko, Pagel, John M., Martinez-Calle, Nicolás, Garcia-Marco, Jose Antonio, Hernández-Rivas, José-Ángel, Miras, Fatima, Coombs, Catherine C., Österborg, Anders, Seddon, Amanda N., López-Jiménez, Javier, Wilson, Matthew R., El-Sharkawi, Dima, Wojenski, Daniel, Ma, Shuo, Munir, Talha, Valenciano, Susana, Seymour, Erlene, Barr, Paul M., Pu, Jeffrey J, Patten, Piers EM, Perini, Guilherme Fleury, Huntington, Scott F, Parry, Helen, Sundaram, Suchitra, Skarbnik, Alan P, Kamdar, Manali, Jacobs, Ryan W, Walter, Harriet Sarah, Walewska, Renata, Broom, Angus, Lebowitz, Sonia, Isaac, Krista, Portell, Craig A, Ahn, Inhye E, Ujjani, Chaitra, Shadman, Mazyar, Skånland, Sigrid S, Chong, Elise A., and Mato, Anthony R.

Abstract

No abstract available

Published
2021

31. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Author

Pinilla Ibarz, Javier, primary, Jurczak, Wojciech, additional, Kambhampati, Suman, additional, Lech Maranda, Ewa, additional, Wróbel, Tomasz, additional, Sharman, Jeff P., additional, Zafar, Syed F., additional, Hoffmann, Marc, additional, Huntington, Scott F., additional, Jacobs, Ryan, additional, Bairey, Osnat, additional, Rowland, Chris, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, Weiss, Michael S., additional, O'Connor, Owen A., additional, and Flinn, Ian W., additional

Published
2021
Full Text
View/download PDF

32. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Author

Jacobs, Ryan, primary, Jurczak, Wojciech, additional, Flinn, Ian W., additional, Grosicki, Sebastian, additional, Giannopoulos, Krzysztof, additional, Wróbel, Tomasz, additional, Zafar, Syed F., additional, Cultrera, Jennifer L., additional, Kambhampati, Suman, additional, Danilov, Alexey V., additional, Burke, John M., additional, Goldschmidt, Jerome, additional, Beach, Douglas F., additional, Huntington, Scott F., additional, Pinilla Ibarz, Javier, additional, Sharman, Jeff P., additional, Siddiqi, Tanya, additional, Brander, Danielle M., additional, Shadman, Mazyar, additional, Pagel, John M., additional, Dlugosz-Danecka, Monika, additional, Ghosh, Nilanjan, additional, Kolibaba, Kathryn S., additional, Sportelli, Peter, additional, Miskin, Hari P., additional, O'Connor, Owen A., additional, Weiss, Michael S., additional, and Gribben, John G., additional

Published
2021
Full Text
View/download PDF

33. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Author

Park, Jae H, primary, Winer, Eric S., additional, Huntington, Scott F., additional, von Keudell, Gottfried, additional, Vemuri, Shreya, additional, Shukla, Madhulika, additional, Kinoshita, Julie C, additional, Falco, Victoria, additional, Gore, Steven D., additional, Stone, Richard M., additional, Abdel-Wahab, Omar, additional, and Tallman, Martin S., additional

Published
2021
Full Text
View/download PDF

34. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

Author

Goyal, Gaurav, primary, Lau, Krystal W., additional, Wang, Xiaoliang, additional, Davidoff, Amy J., additional, Huntington, Scott F., additional, Jamy, Omer Hassan, additional, Calip, Gregory, additional, Shah, Harsh, additional, Stephens, Deborah M., additional, Miksad, Rebecca A., additional, Parikh, Ravi, additional, Takvorian, Samuel, additional, Neparidze, Natalia, additional, and Seymour, Erlene K, additional

Published
2021
Full Text
View/download PDF

39. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Author

Neparidze, Natalia, primary, Lau, Krystal W., additional, Wang, Xiaoliang, additional, Davidoff, Amy J., additional, Huntington, Scott F., additional, Jamy, Omer Hassan, additional, Calip, Gregory, additional, Shah, Harsh, additional, Stephens, Deborah M., additional, Miksad, Rebecca A., additional, Parikh, Ravi, additional, Takvorian, Samuel, additional, Goyal, Gaurav, additional, and Seymour, Erlene K, additional

Published
2021
Full Text
View/download PDF

43. sj-doc-1-tah-10.1177_20406207211043404 ��� Supplemental material for Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States

Author

Shallis, Rory M., Wang, Rong, Bewersdorf, Jan P., Zeidan, Amer M., Davidoff, Amy J., Huntington, Scott F., Podoltsev, Nikolai A., and Ma, Xiaomei

Subjects
hemic and lymphatic diseases, FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-doc-1-tah-10.1177_20406207211043404 for Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States by Rory M. Shallis, Rong Wang, Jan P. Bewersdorf, Amer M. Zeidan, Amy J. Davidoff, Scott F. Huntington, Nikolai A. Podoltsev and Xiaomei Ma in Therapeutic Advances in Hematology

Published
2021
Full Text
View/download PDF

44. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

45. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Author

Gribben, John G., Jurczak, Wojciech, Jacobs, Ryan W., Grosicki, Sebastian, Giannopoulos, Krzysztof, Wrobel, Tomasz, Zafar, Syed F., Cultrera, Jennifer L., Kambhampati, Suman, Danilov, Alexey, Burke, John M., Goldschmidt, Jerome, Beach, Douglas F., Huntington, Scott F., Pinilla Ibarz, Javier, Sharman, Jeff P, Siddiqi, Tanya, Brander, Danielle M., Pagel, John M., Kolibaba, Kathryn S., Dlugosz-Danecka, Monika, Ghosh, Nilanjan, Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A., Weiss, Michael S., and Flinn, Ian W.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results